Stetson University Receives $266,000 NSF Grant for New Microscope
Faculty, students to use the inverted fluorescent microscope in
biology, health sciences, physics research
DELAND, Florida, Sept. 18, 2019 -- Stetson University has received a $266,000 Major Resource Instrumentation Grant from the National Science Foundation (NSF) to purchase an inverted fluorescent microscope system capable of imaging over a wide range of living biological samples from subcellular structures to small organisms.
The microscope system will be used at Stetson to engage undergraduate students across biology, health sciences and physics in superior training through faculty-mentored research projects, and promote the implementation of inquiry-based lab experiences for students in upper-level biology and physics courses.
“This really opens up new avenues of research at the cell and, especially, the sub-cell level at Stetson,” said Holley Lynch, PhD, assistant professor of physics and Stetson’s principal investigator. “We have a growing number of researchers who work with that scale in three departments. And it will allow students to use a research-grade microscope.”
Lynch noted that while some of Stetson’s science faculty/researchers need to see “very small things, such as look inside cells,” others need to see how cells behave over time. The new system, which is expected to arrive on campus later this fall, is “flexible,” she said.
“I see this as a really good stepping-stone. Having this equipment here enables us to apply for other kinds of grants that will fund our research and take our students to the next level,” said Heather Evans-Anderson, PhD, assistant professor health science and a co-principal investigator along with Lynn Kee, PhD, assistant professor of biology; and Roslyn Crowder, PhD, associate professor of biology.
Highlights of the anticipated research: 1) tracking migrating cells in living tissues to link cellular and subcellular mechanisms to tissue-scale movements; 2) examining improperly located cell death proteins in malignant cells; 3) dissecting communication pathways that regulate cardiac myocyte cell proliferation and regeneration in Ciona intestinalis; 4) examining spatial organization and dynamics of iridescent marine bacteria; and 5) promoting education through use of CRISPR/Cas9 gene editing technology by undergraduates in a Genetics course to manipulate and label genes in order to visualize effects in living organisms.
Also, the system will provide a substantial foundation to support and enable fundamental pioneering research by junior faculty members, and foster sophisticated capstone research for seniors under the mentorship of faculty members committed to student training and advancing the participation of underrepresented and minority undergraduates in the sciences.
Collectively, these invaluable experiences will promote scientific competency in students as they achieve a comprehensive range of career goals and contribute to the development of the next generation of scientists.
In 2018, Kresge Foundation funds led to Stetson’s acquisition of an advanced stereo microscope, which effectively aids in the visualization of tissue layers and development of organisms. The new microscope system will deliver even greater power of magnification and capability to see inside cells, Evans-Anderson said, adding that extensive interdepartmental collaboration will result.
The NSF, created by the United States Congress in 1950 to “promote the progress of science,” among other initiatives, deemed the Stetson grant’s intellectual merit and broader impacts a reflection of its statutory mission and worthy of funding. The Major Research Instrumentation Grant program accepted 805 funding proposals, requesting more than $557 million, and only 130 to 145 awards were given.
With an annual budget of $8.1 billion, NSF is the funding source for approximately 27 percent of the total federal budget for basic research conducted at U.S. colleges and universities.
About Stetson University
Founded in 1883, Stetson University is the oldest private university in Central Florida. Stetson focuses on intense learning experiences in a supportive community that allows students to develop their voice in a connected, inclusive environment. Stetson University ranks No. 5 on U.S. News & World Report’s 2019 list of Best Regional Universities (South), and has been recognized as one of The Princeton Review’s 385 Best Colleges, 2020 edition. Stay connected with Stetson on social media.
Biosimilars Working Group Responds to Phase II of the BC PharmaCare Biosimilars Initiative
VANCOUVER, Sept. 18, 2019 /CNW/ - On September 5, 2019, the BC government announced phase two of its Biosimilars Initiative, informing patients prescribed the originator biologic drug, Remicade® (infliximab), to treat inflammatory bowel disease (Crohn's disease and ulcerative colitis) that this medication will no longer be covered by the province, and that they must switch to a biosimilar infliximab, either Inflectra® or Renflexis®.1 This means that patients have only six months to meet with their gastroenterologist to discuss switching their medication and to start a replacement product. The sweeping change in coverage is driven by the government's decision to generate significant healthcare savings from switching patients' medication rather than negotiating with the makers of the originator biologic to lower their prices.
Biologics are medicines created from living cells and are used to treat a variety of conditions, such as Crohn's disease, ulcerative colitis, diabetes, rheumatoid arthritis, cancer, osteoporosis, psoriasis, HIV, multiple sclerosis, and growth deficiencies, to name a few. Biosimilars are highly similar to an originator biologic, but different enough to be sold under their own brand name. Because these drugs are made from living cells, it is impossible to create an identical copy regardless of the use of the exact same manufacturing conditions, ingredients, and process.2 This is a stark comparison to generic drugs, which are made up of chemicals that can be reproduced with the same active ingredient as the original brand name product.3
Health Canada considers a biosimilar to be safe, effective, and of good quality, and highly similar to the originator biologic it references. For a number of reasons, including that the biosimilar companies do not have to invest in discovery and clinical trials, these medicines provide lower-cost options for public payers. However, as the originator biologics are now off-patent, the companies that own these products are willing to negotiate lower prices. Unfortunately, public drug plans prefer to support a biosimilar market.
It is important to note that biosimilars, unlike generic medications, are not interchangeable with the innovator biologic medication. Health Canada set the bar, saying, "Biosimilars are not generic biologics and many characteristics associated with the authorization process and marketed use for generic pharmaceutical drugs do not apply. Authorization of a biosimilar is not a declaration of pharmaceutical equivalence, bioequivalence or clinical equivalence to the reference biologic drug." Be wary of anyone who calls biosimilars "biogeneric", as this is an unacceptable, made-up word for these products.
Health Canada further states that the treating physician, in consultation with the patient, should make the decision to switch a patient after taking into account available clinical evidence.
Canada is the only country in the world to have comprehensive patient support programs paid for by the pharmaceutical companies. This means patients receiving intravenous infusions will need to switch to another group and location to receive their treatment, which could add further stress as they adjust to a new location of care and a new support staff.
The change in coverage is estimated to affect 1,700 patients. This is in addition to about 20,400 British Columbians diagnosed with ankylosing spondylitis, diabetes, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis affected from phase one of the Biosimilars Initiative. This population includes pediatric patients, while pregnant patients may be provided exceptional coverage following approval of request from PharmaCare's Special Authority branch.4
The Biosimilars Working Group, a diverse cohort of health patient groups dedicated to ensuring the best outcomes for patients, welcomes the BC government's expansion for access to healthcare services, such as full coverage for the fecal calprotectin test and increased funding for nursing support. However, the cost-driven objective of the forced-switch policy is worrisome as it fails to put physician wisdom, patient choice, appropriateness of care, accessibility, and affordability at the forefront of health policy. Patients should only switch if they decide that this is the best course of action for their conditions, with consultation from their treating physician.
Gail Attara, President & CEO of the Gastrointestinal Society, and member of the Biosimilars Working Group, shared that, "Every disease area is unique and each needs to be treated differently. Patients with limited therapeutic options should not be lumped together with those who have a broader range of options available to them. Many people depend on public coverage and only a select few have private health plans that do better."5
Surveys conducted on various healthcare stakeholders, including patients, physicians, family caregivers, and the public, in Canada and abroad, reveal synonymous conclusions that treatment decisions should remain between a patient and their physician. Health Canada also encourages patients to speak with their treating physician about switching.6
In 2017, five patient organizations collaborated on a project that surveyed Canadian patients with inflammatory diseases about their perspectives on biologics and biosimilars. Of the 657 individuals surveyed, a vast majority reported being opposed to a forced switch for non-medical reasons.
"We are deeply concerned about the risks associated with a switch. Already, patients with loss of vision depend on accessibility and informed consent when being administered treatments. Furthermore, patients who are stable on a biologic treatment should not be made to potentially jeopardize their safety and quality of life with a mandated switch," said Louise Gillis, National President of the Canadian Council of the Blind.
Biosimilars in oncology are expected to increase in the Canadian market and the implementations made by the BC government concern many cancer patients. "While we are aware of the value of biosimilars, the Canadian Cancer Survivor Network believes that patients who are being successfully treated by biologics should not be forced to switch. Any such decisions should be made by patients in consultation with their clinicians," shared Jackie Manthorne, President & CEO of the Canadian Cancer Survivor Network.
The BC Ministry of Health precipitates the need to increase biosimilar uptake due to best practices in the European market, having had over a decade of experience with these products. The Alliance for Safe Biologic Medicines (ASBM), an international and multi-stakeholder organization comprised of healthcare groups, patients, physicians, and biotechnology companies, responded to the BC announcement by releasing a fact sheet analyzing the claims purported by the provincial government.7 "European countries, for example, enjoy robust biosimilar markets and higher uptake rates, yet the vast majority leave the decision on what biologic medicine to use with the treating physician, in consultation with their patient. No country in Europe has ceased the reimbursement of originator biologics by a government decree such as that issued in BC and only very few countries use a procurement process that will reimburse a single product that wins the bid," said Michael Reilly, Executive Director of ASBM.8
The Biosimilars Working Group will continue to raise the importance of patient choice and evidence-based decision making with policymakers. To lean more about this group and to stay up-to-date with biosimilars research and policies, please visit www.biosimilaroptions.ca and follow @BiosimilarsWG on Twitter.
Working Group Members Participating in This Media Release: Alliance for Safe Biologic Medicines Canadian Cancer Survivor Network Canadian Council of the Blind Canadian Society of Intestinal Research Gastrointestinal Society
5 Gail Attara, "Balancing Act: Cost Containment vs. Patient Health Outcomes," GI Society Canadian Society of Intestinal Research, available at https://badgut.org/balancing-act/, Accessed 2019-09-11.
By now, virtually everyone knows the importance of living an active lifestyle. Working out helps boost your fitness levels and decreases the risk of certain diseases. Incorporating the principles of martial arts into your exercise routine can have a very positive impact. Here are five principles to remember.
Display Discipline
Maintaining a disciplined mindset is one of the biggest principles of Shaolin martial arts. As you may have experienced, motivation often comes and goes. There will be times when you simply don’t want to work out. However, disciplined people fight the temptation to take days off. They recognize the value of sticking to their regimen.
Don’t Give Up
The process of becoming fit isn’t always easy. When results don’t happen fast enough, it’s not uncommon for a person to give up. The principles of martial arts teach you to keep pushing past obstacles. Warriors never allow setbacks to stand in their way. Always keep your goals in sight. If you need a little extra inspiration, wear a Jiu-jitsu t-shirt.
Take Care of Your Body
Martial artists must stay prepared for battle. Nurturing their body is especially critical. Try to implement this same principle in your life. By taking care of your basic health, you will have greater stamina. The extra energy will help you to exercise more efficiently. Strive to eat nutritious meals on an everyday basis. If you are dealing with an injury, give your body enough time to heal. Getting a good night’s sleep is just as essential.
Put Forth Great Effort
To be a great martial artist, one must put forth a valiant effort. During your exercise routine, remember the importance of putting your best foot forward. Working hard is bound to pay off in the long run. Even if you’re in a bad mood, never make the mistake of developing a lazy attitude.
Mind Over Matter
Martial arts involves more than just kicking and punching. In fact, a person’s mind is actually their most powerful weapon. While exercising, try to maintain a clear and focused mind. Don’t allow any personal issues to ruin your workout. Concentrate solely on your fitness regime. Small things, like keeping a good posture and breathing effectively, can make a big difference.
The principles of martial arts can take your exercise routine to the next level. Develop the psyche of a true champion. A few changes will help you to achieve great success.
Scotiabank supports young Canadians with a $500,000 donation to the Terry Fox PROFYLE program
TORONTO, Sept. 18, 2019 /CNW/ - Scotiabank has donated $500,000 to the Terry Fox Foundation PROFYLE program, to help give young Canadians with hard-to-treat cancers access to potentially life-saving treatment.
The Terry Fox PROFYLE – short for PRecision Oncology For Young peopLE – is a unique program that uses precision medicine to treat qualifying babies, children and young adults across Canada. Through this project, patients who are out of treatment options have their tumours and genomes profiled and analyzed, and are connected to a network of top cancer researchers. This helps to identify drugs that might work for these patients based on the molecular profile of their tumours.
"Young people are our future leaders and Scotiabank's goal is to help ensure that they have the necessary resources they need to support their success," says Karen Soos, Director of Philanthropy at Scotiabank. "We are investing in Terry Fox PROFYLE to help young people thrive and reach their infinite potential through improved access to the best healthcare. This program gives another chance to young people who have been told there are no more treatment options."
Scotiabank and its employees are focused on enriching the lives of young people in the community. Through this donation, Scotiabank hopes to give more young people resources to help them grow into healthy, contributing adults. The Terry Fox PROFYLE program began in 2017 and today more than 300 children enrolled.
"We are so grateful for the support and commitment of Scotiabank in helping us to find new treatments and more answers for the 20% of children, adolescents, and young adults with hard-to-treat cancers," says Heather Scott, Director of Development at The Terry Fox Foundation. "Terry Fox PROFYLE is an unprecedented Pan-Canadian precision medicine project that is showing promising results towards this goal. This initiative is possible thanks to the generosity of our donors like Scotiabank."
Scotiabank has had a long relationship with the Terry Fox Foundation, dating back to Terry's Marathon of Hope in 1980. Donations for the Terry Fox Run can be made at Scotiabank branches across Canada.
About Scotiabank
At Scotiabank, we aim to support organizations that are committed to helping young people reach their infinite potential. Young people are our future leaders and Scotiabank's goal is to help ensure that they have the necessary skills and resources they need to support their success. Together with our employees, the Bank supports causes at a grassroots level. Recognized as a leader for our charitable donations and philanthropic activities, in 2018, Scotiabank contributed more than $80 million to help our communities around the world.
Scotiabank is Canada's international bank and a leading financial services provider in the Americas. We are dedicated to helping our more than 25 million customers become better off through a broad range of advice, products and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. With a team of more than 100,000 employees and assets of over $1 trillion (as at July 31, 2019), Scotiabank trades on the Toronto Stock Exchange (TSX: BNS) and New York Stock Exchange (NYSE: BNS). For more information, please visit www.scotiabank.com and follow us on Twitter @ScotiabankViews.
SOURCE Scotiabank
Spin Before You Spend: Our Favorite Free Online Spin Classes & Workout Videos
Still on the fence about Spinning? This is your lucky day, because we’ve collected 6 free Spin classes that might change your mind.
But a word of caution: Not All Spin Classes Are Created Equal!
Nothing else can get you to those fat-burning heart rate zones like Spin. And with this 28-minute ride, our fearless leader Cat Kom will absolutely put your heart through the ringer and back. Get ready, because you’re headed to the cardio zone.
Are you a beginner Spinner or a cycling savant? No matter your skill level, this power-focused cycling workout just needs 20 minutes to get your heart absolutely pumping.
This free Spinning class is quick, but it ain’t easy. In just a half-hour, Cat will guide you through smooth jumps, fat-burning sprints, and climbs that’ll leave you shaking at the knees. But trust us—you’re going to feel amazing after this one.
Defy gravity with this intense climb that’ll push your quads to the absolute limit. Think you can take it? This class goes an incredible 45 minutes, meaning you’ll absolutely work your cardio and sculpt your legs.
Avicanna (TSX: AVCN) Enters an Exclusive Research Agreement with the University of Guelph for Proprietary Cannabinoid-based Products and Formulations to Treat Psychiatric Disorders
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS./
TORONTO, Sept. 13, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that it will further the research and development and pre-clinical analysis of its proprietary prescription and over-the-counter ("OTC") cannabinoid products and formulations through an exclusive research agreement with the University of Guelph in Canada for a project to be performed by Dr. Jibran Khokhar, Assistant Professor at the University of Guelph, Ontario Veterinary College, Department of Biomedical Sciences, as principal investigator.
"We believe the studies that we have designed with Dr. Khokhar, which will be performed by his team at the University of Guelph, will provide a unique opportunity to evaluate disorders of brain health and are an essential step in a committed research program for evaluating the role of cannabinoids as therapies for several human neurological disorders," said Dr. Amza Ali, the Company's Chief Medical Officer.
The collaboration with the University of Guelph will focus on evaluating a variety of dosage forms on preclinical models of several human psychiatric conditions, including depression, anxiety, schizophrenia, PTSD and substance abuse. A unique aspect of this collaboration is to determine brain cannabinoid levels and cerebral activity function using electrophysiology and behavioral methods with various Avicanna formulations and common to rare cannabinoids.
Additional studies include research in the treatment of nicotine and alcohol addiction with the use of various cannabinoid formulations provided by Avicanna. Analysis of vaporizer formulations amongst others will be tested on preclinical models of neuropsychiatric disorders to potentially reduce/replace doses of THC with CBD.
"Avicanna is focused on elevating the scientific research related to cannabinoid products through its collaborations with world-class research institutions in order to provide patients and physicians with products that offer a well understood mechanism of action, efficacy, and safety profile. We are excited to advance our research and development program for psychiatric disorders and substance dependency, building on our data and expertise within the cannabinoid market," stated Aras Azadian, Chief Executive Officer.
The services to be performed under the research agreement will be provided on an exclusive basis and Dr. Khokhar's laboratory has agreed to not conduct testing on any formulations or products similar to the Company's products during the term of the agreement. All research data and research reports created under the research agreement will remain the sole property of Avicanna, however, Avicanna has granted a license to the University of Guelph to use such reports and data for research and academic purposes. The studies under this agreement are expected to take two (2) years and the cost of the studies are expected to be approximately $300,000.
About Avicanna
Avicanna is an Ontario corporation focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products through its two main business segments, cultivation and research and development.
Avicanna's two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia are the base for Avicanna's cultivation activities. These two companies are licensed to cultivate and process cannabis for the production of cannabis extracts and purified cannabinoids including cannabidiol (CBD) and tetrahydrocannabinol (THC).
Avicanna's research and development business is primarily conducted out of Canada at its headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto. Avicanna's scientific team develops products, and Avicanna has also engaged the services of researchers at the Leslie Dan Faculty of Pharmacy at the University of Toronto for the purpose of optimizing and improving upon its products.
Avicanna's research and development and cultivation activities are focused on the development of its key products, including plant-derived cannabinoid pharmaceuticals, phyto-therapeutics, derma-cosmetics and Extracts (defined as plant-derived cannabinoid extracts and purified cannabinoids, including distillates and isolates), with a goal of eventually having these products manufactured and distributed through various markets.
Stay Connected
For more information about Avicanna, visit www.avicanna.com, call 1-647-243-5283, or contact Setu Purohit, President by email info@avicanna.com.
Cautionary Note Regarding Forward-Looking Information and Statements
Certain information in this press release contains forward-looking statements. Such statements include but are not limited to the intended outcomes of the studies to be conducted under the research agreement, the disorders to be studied and the expected term and cost of the studies. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict, including the risk factors set out under the heading "Risk Factors" in the Company's long form final prospectus dated July 8, 2019. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements, unless and until required by securities laws applicable to the Company.
SOURCE Avicanna Inc.
Japanese Goku Spa Offers Innovative Techniques To Help Americans Finally Get To Sleep
More than a third of American adults are not getting enough sleep on a regular basis, according to a study in the Centers for Disease Control and Prevention’s (CDC) Morbidity and Mortality Weekly Report. Atsumi Kaneda, founder of US based Goku Spa (www.gokusleep.com) hopes to help reverse this trend. "We refer to Goku as the "ultimate sleep" spa because we exclusively focus on the scalp." said Atsumi Kaneda. "Our techniques are designed to put in an individual in the most relaxed state possible to ensure they drift off into a peaceful slumber." Kaneda founded Goku in 2008 in Japan after suffering from years of insomnia. Kaneda was constantly exhausted during the day as a result of poor quality sleep. Seeing that self-care in Japan was a growing trend, Kaneda sought to solve her own problem as well as bring that solution to others. "Since there were no market for head massage, there were no books nor school for it. I had to invent it myself." Said Kaneda. "I studied under various doctors, acupuncturists, and healers to gain knowledge and techniques about what induces maximum relaxation and puts the body in the optimal state for sleep ." Kaneda created her special form of treatment called Zecchou Sleep (meaning "ultimate sleep"), which is done without water or oil. The technique is composed of twenty-one types of strokes. Pressure and direction using the fingers are applied to the scalp, facia, and muscles of the head. The therapists hands move slowly to lose the move the muscles of the head which result in more blood flow and circulation. Beneath the scalp are the large fascia and some thin muscles. "The pressure slowly stimulates the parasympathetic nerves system, and leads the clients to wonderful sleep. This sleep is different from meditation or nighttime sleep, it is a new experience of a pleasurable dreamy land." said Kaneda. "In addition the treatment, each Goku spa has visually soothing lights and music which can enhance the experience." Goku's four locations in Japan have become so popular, that there are currently 498,721 people on the waiting list for appointments. In 2019, Kaneda opened her first Goku spa in the US rightfully so in New York which is known as "the city that never sleeps." "Our mission is to alleviate sleep difficulties and discomfort. We want to make insomniacs sleep. We want you to experience joyful and pleasurable sleep, and make your dreams more colorful. If Goku’s treatment and experiences can bring joy and relieve any pain you have during sleep, that is my greatest pleasure." said Kaneda. For more information about Goku spa, please call (929) 336-3088 and visit: https://www.gokusleep.com/ For all interviews please call Ryan McCormick of Goldman McCormick Public Relations (www.goldmanmccormick.com) at 516-901-1103 / 919-377-1200
Santé Cannabis and Spectrum Therapeutics Launch Transformative Medical Cannabis Training Program for Québec Healthcare Professionals
MONTREAL and SMITHS FALLS, ON, Sept. 16, 2019 /CNW/ - Québec doctors have a new tool at their disposal for learning about medical cannabis and its viability as a treatment option for their patients.
Santé Cannabis, a pioneer in medical cannabis in Québec, has partnered with Spectrum Therapeutics, the medical division of Canopy Growth (TSX: WEED) (NYSE: CGC) to launch the Prescriber Training Program, designed to aid physicians and patients, announced today at the new Santé Cannabis clinic and research centre in Montréal.
This new initiative developed by Santé Cannabis equips physicians with the most up-to-date clinical guidelines, support networks, online and in-person training opportunities so they can prescribe and monitor cannabinoid treatment plans with confidence. The program will be offered for free to Québec physicians and is made possible by an unrestricted educational grant from Spectrum Therapeutics.
"Patient referrals and training requests from our physician colleagues have increased by more than 500 per cent over the last year," says Dr. Michael Dworkind, Medical Director of Santé Cannabis and McGill University Associate Professor of Family Medicine. "It is our duty as physicians to understand the available treatment options for our patients, and medical cannabis treatments have emerged as an important clinical tool. In this program, we extend our experience and expertise to healthcare professionals, in order to support them to meet the needs of their patients."
The Prescriber Training Program is designed by clinicians for clinicians, and gives a unique, practical approach to medical cannabis learning. It provides participating physicians with:
Self-learning modules that detail treatment evidence for specific conditions and symptoms;
Ongoing personalized phone support for questions about medical cannabis and patient care;
Clinical preceptorship opportunities at four Santé Cannabis locations across Québec;
Practical reference guidebook on developing and managing treatment plans and dosing; and
Clinical toolkits to help navigate patient assessment and follow-ups.
"A significant issue preventing the consideration of cannabinoid medicine by healthcare professionals is that the topic is not typically included in the medical school curriculum," comments Dr. Mark Ware, Chief Medical Officer, Canopy Growth. "We've invested in a range of training and education initiatives to address this gap in knowledge, and this new program creates an important resource for Québec physicians interested in learning how to integrate medical cannabis into their practice."
As Québec's first and foremost medical cannabis clinic and research centre, Santé Cannabis has received referrals from more than 2,500 physicians and assessed over 6,000 patients since 2014, while also providing information sessions for patients and healthcare professionals. Spectrum Therapeutics' track record with providing industry-leading education, resources and support for healthcare professionals includes:
Evidence-based educational courses in Canada that have been delivered to thousands of physicians, nurses, and pharmacists, including accredited medical education programs through the Canadian Council on Continuing Education in Pharmacy (CCCEP)
A first-of-its-kind Catalyst Peer Mentorship Program, which links physicians from across Canada with colleagues who possess advanced knowledge of the cannabis field in order to provide case-by-case support.
71,000+ interactions with healthcare professionals
Media are invited to attend an open house to learn more about the program and visit the recently expanded Santé Cannabis clinic and research centre in Montréal including a guided tour. Santé Cannabis Medical Director Dr. Michael Dworkind, Practicing Physician Dr. Alain Watier, and Canopy Growth Chief Medical Officer, Dr. Mark Ware will be available for interviews. Event details below:
Date: Tuesday, September 17th 2019 Time: 9:00AM to 5:00PM Address: 225-4150 Rue Sainte-Catherine Ouest, Westmount, H3Z 2Y5 RSVP: If you'd like to attend, please RSVP with Lilia Rassoul (media@santecannabis.ca)
ABOUT SANTÉ CANNABIS Santé Cannabis is Québec's leading specialized medical cannabis clinic and research centre, with clinics operating in Montreal, Quebec City, Sherbrooke and Pointe Claire. Santé Cannabis is a trusted and essential consultative service for over 2500 physicians who have referred more than 12,000 patients since 2014. The clinical care team is comprised of family physicians and specialists in chronic pain, cancer, gastroenterology, and endocrinology, as well as nurses with clinical expertise in cannabis medicine. Santé Cannabis provides online and onsite training for healthcare professionals, researchers, and decision makers from all over the world. As a Contract Research Organization specialized in medical cannabis, Santé Cannabis offers consultation, data management and clinical trial services to a diverse range of clients from pharmaceutical, biotech and cannabis industries.
ABOUT SPECTRUM THERAPEUTICS Spectrum Therapeutics, the medical division of Canopy Growth Corporation (TSX: WEED, NYSE: CGC), is dedicated to educating healthcare practitioners, furthering the public's understanding of medical cannabis and its various applications, and cutting edge, commercializable research and IP development. Founded in Canada, Spectrum Therapeutics operates in Australia, South America, Africa and across Europe. Its products are available in a wide range of potencies and formats designed to simplify the dialogue around strength and dosage by applying a colour-coded spectrum to categorize medical cannabis according to THC and CBD levels.
Spectrum Therapeutics' offerings include whole flower cannabis, oils and new innovations such as Softgels in addition to single cannabinoid medicine Dronabinol under the brand Bionorica Ethics. Through product simplification, robust clinical research and ongoing education of healthcare professionals, Spectrum Therapeutics is committed to addressing the unmet medical needs of patients around the globe.
About Canopy Growth Corporation Canopy Growth (TSX:WEED, NYSE:CGC) is a world-leading diversified cannabis, hemp and cannabis device company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms, as well as medical devices through the Company's subsidiary, Storz & Bickel GMbH & Co. KG. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time. The Company has operations in over a dozen countries across five continents. The Company's medical division, Spectrum Therapeutics is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public's understanding of cannabis, and has devoted millions of dollars toward cutting edge, commercializable research and IP development. Spectrum Therapeutics sells a range of full-spectrum products using its colour-coded classification Spectrum system as well as single cannabinoid Dronabinol under the brand Bionorica Ethics. The Company operates retail stores across Canada under its award-winning Tweed and Tokyo Smoke banners. Tweed is a globally recognized cannabis brand which has built a large and loyal following by focusing on quality products and meaningful customer relationships. From our historic public listing on the Toronto Stock Exchange and New York Stock Exchange to our continued international expansion, pride in advancing shareholder value through leadership is engrained in all we do at Canopy Growth. Canopy Growth has established partnerships with leading sector names including cannabis icons Snoop Dogg and Seth Rogen, breeding legends DNA Genetics and Green House Seeds, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth operates eleven licensed cannabis production sites with over 4.7 million square feet of production capacity, including over one million square feet of GMP certified production space. For more information visit www.canopygrowth.com
Notice Regarding Forward Looking Statements This news release contains "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. Examples of such statements include "most up-to-date clinical guidelines, support networks, online and in-person training opportunities", and "will be offered for free". Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including medical cannabis regulations and such risks contained in the Company's annual information form dated June 24, 2019 and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities laws.
SOURCE Canopy Growth Corporation
7 in 10 Canadians over the age of 65 feel confident about technology use and 86% are online daily
Almost 6 in 10 (58%) own smartphones and 70% would pay out-of-pocket for technology to stay in their own home
TORONTO, Sept. 16, 2019 /CNW/ - A new survey commissioned by AGE-WELL, a federally funded Network of Centres of Excellence, and conducted by Environics Research, offers a number of fresh insights into the attitudes of Canadians over the age of 65 and 50-64 toward aging, health and technology. The survey was conducted July 11 – 30, 2019 with over 2,000 Canadians 50 years of age and older.
"The findings show that Canadians over the age of 65, just like those aged 50 to 64, are feeling confident about using technology and many feel the impact on society is positive," says Bridgette Murphy, Managing Director and COO of AGE-WELL. "We also found strong interest among respondents in using technologies to stay healthy, engaged and living independently for as long as possible."
The poll found that more than 8 in 10 Canadians over the age of 65 believe technological advances can help older adults stay safe, in their own homes longer and stay independent. And, 7 in 10 agree that technological advancements can help older adults stay active and manage health better as they age and can reduce social isolation. When they have difficulties with technology, 53% of respondents turn to their children and 18% to their grandchildren.
"With this level of receptivity and usage, we have an incredible opportunity to create products that will help people age well and remain in their own homes longer," says Murphy. "Overall, the survey reaffirms our view that, as a country, we are well positioned to be a world leader in the field of technology and aging."
Among the key findings of this survey:
Attitudes towards Technology
74% of those aged 65+ and 80% of those aged 50-64 report feeling confident using current technology;
Only 15% of Canadians over the age of 65 and 50-64 believe the impact of technology on society is negative; 6 in 10 (61%) over the age of 65 believe the impact of technology on society is positive;
7 in 10 (70%) of Canadians 65 and over and 67% of those aged 50-64 would be willing to pay out-of-pocket for technology that allows them to stay in their home longer.
Technology for Health and Wellness
Over 90% of those aged 50-64 and 65+ have never had an online 'visit' with a doctor or health care provider;
18% of Canadians aged 65+ and almost ¼ (24%) of those aged 50-64 use a digital watch to help manage their health, wellness and/or independence;
Over 8 in 10 Canadians 65+ believe technological advancements can help older adults stay safe, independent and stay in their own homes longer; 7 in 10 agree technological advancements can help older adults reduce social isolation; stay active and manage their health better as they age;
7 in 10 Canadians over the age of 50 would use the following technology for health and wellness: devices that alert people if you fall, that keep you mentally active at home, that help you recover at home, that help connect you with a doctor/health care provider and that allow you to stay independent at home.
Technology for Connecting
86% of Canadians aged 65+ and 94% of Canadians aged 50+ report being online daily;
58% of Canadians aged 65+ and almost 8 in 10 (78%) aged 50-64 own smartphones;
Almost all (93%) of smartphone owners aged 65+ find them easy to use and 98% of those owning smartphones aged 50-64 find them easy to use;
Over 6 in 10 (63%) Canadians aged 65+ have a Facebook account. Over 8 in 10 (88%) of Canadians aged 50-64 currently have at least one social media account (Facebook 72%, YouTube 46%);
When they have difficulties with technology, Canadians aged 65+ turn to their children most often (53%) and sometimes their grandchildren (18%).
About the Survey: Commissioned by AGE-WELL, the Environics Research survey was conducted between July 11 - 30, 2019, interviewing 2,027 Canadians over the age of 50. 602 respondents (30%) for this survey were contacted by telephone and 1,425 (70%) via an online panel.
About AGE-WELL: AGE-WELL NCE Inc. is Canada's Technology and Aging Network. The pan-Canadian network brings together researchers, older adults, caregivers, partner organizations and future leaders to accelerate the delivery of technology-based solutions that make a meaningful difference in the lives of Canadians. AGE-WELL researchers are producing technologies, services, policies and practices that improve quality of life for older adults and caregivers, and generate social and economic benefits for Canada. AGE-WELL is funded through the federal Networks of Centres of Excellence program. www.agewell-nce.ca.
SOURCE AGE-WELL Network of Centres of Excellence (NCE)
Smokers' Rights to Know about Less Harmful Alternatives Undermined by Provincial Governments
TORONTO, Sept. 16, 2019 /CNW/ - According to Research Co.'s survey for the Canadian Association of Consumers, only 25 percent of smokers who sought advice from a physician on how to quit had vaping mentioned as an option and referenced as a potential harm reduction tool. Only 33 percent of smokers surveyed believed the products were less harmful than tobacco.
This new information comes on the heels of a decision by the Ontario government to sign a joint submission in which Canada's ten provinces and three territories demand that the federal government impose further restrictions on vaping advertising.
"If vaping advertising is prohibited and health officials are ill-equipped to advise smokers about these less harmful alternatives, it begs the question, how can public health advocates reach adult smokers to inform them of the full suite of options available to help them reduce their dependence on tobacco?" said Professor Chris Lalonde, academic advisor to Rights4Vapers.com, a consumer advocacy group dedicated to advancing evidence-based policymaking. "There is a clear need for more information on harm reduction products in Canada. Adults smokers understanding of vaping products contrasts with Health Canada's position that vaping is less harmful than smoking and offers smokers a potentially effective means to quit smoking."
Judges in two recent court cases ruled that policies that may prevent smokers from becoming aware of less harmful alternatives are a form of public health censorship and are unconstitutional.
Also, several federal and provincial regulations already exist that restrict vaping advertising to limit the appeal of these products to youth. Quebec's provincial regulations go the furthest to prevent vape retailers from advertising their products altogether, even where cigarettes are sold and even in adult-only establishments.
"If advertising is a key driver of youth trying vaping products, one would expect the ban on advertising in Quebec to result in lower rates of youth experimentation, but this is not the case," argues Professor Lalonde. "The youth experimentation rate is nearly equal to that of provinces with no vaping advertising restrictions. Advertising is not the key driver to youth uptake of vaping products."
Before the federal government introduces regulations requiring all other provinces to follow suit, regulators should also remember that a Quebec superior court judge recently found provincial restrictions on vaping advertising to violate the Canadian Charter of Rights and Freedoms. Namely integrity and personal security as well as freedom of expression. The judge concluded that; "The problem with the current restrictions is that the public—particularly smokers—do not distinguish between smoking and vaping… they must be permitted to know the difference. Rather than silence, it is sometimes necessary to educate and let people know that vaping exists first and foremost for smokers."
In the same vein, Facebook recently lost a lawsuit filed by a non-governmental organization which argued that the social media giant's policies have the effect of censoring posts on harm reduction, jeopardizing the ability for the public health groups to share information that could save lives. The case outlined the "problem of Facebook deleting pages, groups, posts, and that promoted harm reduction principles and products."
"In its consideration of further restrictions on advertising to protect youth,Rights4Vapers.com strongly urges the Canadian government to carefully weigh these concerns with the acknowledgment that adult smokers do not know enough about vaping nor do their trusted health providers," concluded Professor Lalonde.
SOURCE Rights 4 Vapers
TRAIN IT RIGHT NEWSLETTER
Sign Up and get a free 7 day Train it Right HIIT Program!
